Mary Anne Heino has been the CEO of Lantheus Holdings since 2015, stepping into the role after serving as the Chief Operating Officer and Chief Commercial Officer. With a strong background in healthcare, she has experience in leading companies in...

Mary Anne Heino has been the CEO of Lantheus Holdings since 2015, stepping into the role after serving as the Chief Operating Officer and Chief Commercial Officer. With a strong background in healthcare, she has experience in leading companies in the pharmaceutical sector for over 25 years. Heino’s educational journey includes an MBA from NYU’s Stern School of Business, along with degrees in nursing and biology, showcasing her thorough grounding in both science and business. Under her leadership, Lantheus has expanded its focus on innovative diagnostic imaging products, vital for detecting and treating diseases. Notably, her compensation reflects a mix of salary and performance bonuses, which shows that her earnings align with the company’s success. Mary Anne is not just a leader; she's navigated through challenges, like steering the company through the disruptions of the pandemic and executing significant acquisitions, all while focusing on employee safety and operational continuity. Recently, she announced her retirement as CEO effective March 2024 but will remain with the company as a board member and chairperson. This transition indicates a smooth handover as the company plans its future and continues to grow in the healthcare landscape.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Lantheus Holdings CEOs

L

Mary Anne Heino

Ex-CEO of Lantheus Holdings

Education

Master's in Business Administration from the Stern School of Business at New York University; Bachelor of Science in Nursing from the City University of New York; Bachelor of Science in Biology from the State University of New York at Stony Brook

Field of Expertise

Healthcare & Life Sciences - Healthcare

Sector of Economy

Healthcare

Born

January 1, 1960 - 65 years ago

CEO of Lantheus Holdings for

8 years 6 months (Aug 2015 - Mar 2024)

Previous Experience

Chief Operating Officer at Lantheus Holdings, Inc.; President and Senior Vice President of Worldwide Sales and Marketing at Angelini Labopharm LLC and Labopharm USA; Various roles at Centocor, Inc.

Rivals

Competitors/colleagues of Mary Anne Heino

Holdings

See how much did Mary Anne Heino make over time.

Mary Anne Heino has been active in trading Lantheus Holdings stock, especially notable in 2022 and 2023. In March 2023, her trading peaked at an impressive $107.94 million, illustrating her confidence in the company’s trajectory. This was a notable increase...

Mary Anne Heino has been active in trading Lantheus Holdings stock, especially notable in 2022 and 2023. In March 2023, her trading peaked at an impressive $107.94 million, illustrating her confidence in the company’s trajectory. This was a notable increase compared to previous years, where her trading ranged from around $8 million to $20 million monthly. The volatility in her trading suggests a strategic move, likely connected to major company milestones such as product launches and financial achievements. At one point, Heino's wealth in Lantheus stock was substantial, translating her position not just in salary but also reflecting her commitment to the company’s growth.

Loading...

Total Stock Sold

$42.97M

LNTH

$42.97M

867,824 LNTH shares

What if they kept their stock?

If Mary Anne Heino didn't sell their stock, today they would have:
Extra LNTH867,824 shares worth $9.62M.
This is -77.6% and $33.34M less than what they got when they sold the stock.

Charitable Transactions

LNTH

69,368 shares

LNTH

Recent Charitable Transactions

LNTH

8,618 shares

LNTH

Jun 7, 2024

Charity

LNTH

53,350 shares

LNTH

Dec 13, 2023

Charity

LNTH

3,000 shares

LNTH

Mar 4, 2021

Charity

LNTH

4,400 shares

LNTH

Dec 31, 2020

Charity

Insider Trading

See recent insider trades of Mary Anne Heino.

LNTH

8,618 shares

LNTH

Jun 7, 2024

Charity

LNTH

$272.09

LNTH at $90.70/share

Jun 7, 2024

Sale

LNTH

8,618 shares

LNTH

Jun 7, 2024

Charity

LNTH

$5.00M

LNTH at $94.20/share

Mar 3, 2025

Sale

LNTH

50,070 shares

LNTH

Mar 3, 2025

Received

LNTH

$1.01M

LNTH at $87.90/share

Nov 8, 2024

Sale

LNTH

$1.01M

LNTH at $95.96/share

Aug 2, 2024

Sale

LNTH

2,635 shares

LNTH

May 9, 2024

Received

LNTH

81,169 shares

LNTH

Mar 4, 2024

Received

LNTH

$6.15M

LNTH at $65.54/share

Mar 4, 2024

Sale

Compensation History

See how much did Mary Anne Heino make over time.

In 2023, Mary Anne Heino's total compensation was about $1.86 million, including a base salary of $886,000 and a bonus of over $1.48 million based on the company’s performance. This mix indicates that her pay is closely linked to Lantheus’s success, rewarding her efforts in achieving financial goals. Heino’s bonuses are based on factors like net revenue and earnings per share, showing how her leadership translates into measurable results for shareholders. Her compensation philosophy emphasizes attracting top talent and aligning leadership goals with company interests. Interestingly, in the prior year (2022), her total compensation was higher at about $2.21 million, primarily due to performance bonuses and stock vesting, reflecting the company's growth trajectory during her tenure. Overall, her compensation package provides insights into both her personal investment in Lantheus and the company’s ambitions in the competitive healthcare industry.

Year

2023

Total Compensation

$2.38M

Salary

$886.00K

Board Justification

The compensation philosophy is designed to attract, motivate, and retain executive talent, aligning their interests with those of shareholders and rewarding performance.

Bonus

$1.48M

Board Justification

Based on the Corporate Performance Factor of 134% and Individual Performance Factor of 125% applied to her target bonus of 100% of her salary.

Other

$13.73K

Board Justification

Includes 401(k) matching contributions.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

The performance metrics include Net Revenue and Bonus EPS, with a Corporate Performance Factor of 134% and an Individual Performance Factor of 125%.

Other Lantheus Holdings CEOs

Here are other CEOs of Lantheus Holdings

Brian Markison

CEO of Lantheus Holdings

March 2024 - Present